【藥品性質提示】 ★必確認適應症：缺血性腦中風(ischemic stroke)、肺栓塞(PE) #建議持續輸注 (IV pump) 之高警訊藥品

栓塞
Acute ischemic stroke: Treatment of acute ischemic stroke as soon as possible but within 3 hours of symptom onset
Pulmonary embolism: Management of acute massive pulmonary embolism
ST-elevation myocardial infarction: Management of STEMI for the lysis of thrombi in coronary arteries. Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy. Thrombolytic therapy is an option in centers without PCI capability, followed by transfer to a PCI-capable center.

Tissue plasminogen activator (TPA) manufactured by DNA technology. It enhances the conversion of plasminogen to plasmin by binding to fibrin, initiating fibrinolysis with limited systemic proteolysis.

1. Patients with active internal bleeding
2. History of cerebrovascular accident, intracranial neoplasm, aneurysm, or recent (within 2 months) intracranial or intraspinal surgery or trama

C

Infant risk can not be ruled out. Breastfeeding women should stop breastfeeding within 24 hours after taking Actilyse.<20230914>

1. Bleeding complications, reperfusion arrhythmias and reinfarction are the primary concerns of therapy
2. Systemic fibrinolysis is less than that seen with streptokinase

ST-elevation myocardial infarction(STEMI):
1. Symptoms onset <6 hours: 15 mg as a bolus, followed by 0.75 mg/kg (up to 50 mg) over 30 min, then 0.5 mg/kg (up to 35 mg) over the next 60 min immediately.
2. Symptoms onset 6-12 hours: 10 mg as a bolus, followed by 50 mg over 60 min, then 40 mg over the next 120 min immediately; for patients <65 kg, Intravenous infusion for 3 hours, do not exceed 1.5mg/kg dosage.<20230914>
Pulmonary embolism(PE):
10 mg as a bolus in 1-2 min, followed by 90 mg over 120 min (up to 100 mg); for patients <65 kg, Intravenous infusion for 2 hours, do not exceed 1.5mg/kg dosage.
Acute ischemic stroke:
0.9 mg/kg (maximum total dose: 90 mg); 10% as an IV bolus over 1 minute, followed by 90% as a continuous infusion over 60 minutes

1. There are no dosage adjustments provided in the manufacturer's labeling.
2. Hemostatic defects due to severe renal disease may increase the risk for bleeding.

1. There are no dosage adjustments provided in the manufacturer's labeling.
2. Significant hepatic impairment and hemostatic defects due to severe hepatic disease may increase the risk for bleeding.

Reconstitute to a concentration of 1 mg/mL with provided sterile water for injection. Do not shake; gently swirl or slowly invert to mix.